Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185

5 Jan 2024

Abstract excerpt

including strains with or without production of serine carbapenemases. After its launch, emergence of ceftazidime-avibactam-resistant strains that produce mutated β-lactamases capable of efficiently hydrolyzing ceftazidime or impairing avibactam inhibition are increasingly reported. Furthermore, cross-resistance towards cefiderocol, the latest cephalosporin in clinical use, has been observed in some instances....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Cancer therapeutics and mechanisms
Share to Drug Transport and Resistance Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38179965
DOI: 10.1128/mbio.02874-23

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185PMID 38179965Read ↗

High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variantSemantic proximity Read ↗

A Novel CMY Variant Confers Transferable High-Level Resistance to Ceftazidime-Avibactam in Multidrug-Resistant EscherichiacoliSemantic proximity Read ↗

High-level ceftazidime-avibactam resistance in <i>Escherichia coli</i> conferred by the novel plasmid-mediated beta-lactamase CMY-185 variantSemantic proximity Read ↗

Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant Escherichia coliSemantic proximity Read ↗

Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative BacteriaSemantic proximity Read ↗

Resistance to aztreonam-avibactam due to a mutation of SHV-12 in Enterobacter.Semantic proximity Read ↗

Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop DeletionSemantic proximity Read ↗

Evolution of carbapenemase activity in the class C β-lactamase ADC-1Semantic proximity Read ↗

Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections.Semantic proximity Read ↗

Unveiling the evolution routes of TEM-type extended-spectrum β-lactamases.Semantic proximity Read ↗

Aztreonam-avibactam: an option against carbapenem-resistant Enterobacterales with emerging resistanceSemantic proximity Read ↗

Rapid Emergence of Resistance to Broad-Spectrum Direct Antimicrobial Activity of AvibactamSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.